PUBLICATION
Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
- Authors
- Saraiva, S.M., Gutiérrez-Lovera, C., Martínez-Val, J., Lores, S., Bouzo, B.L., Díez-Villares, S., Alijas, S., Pensado-López, A., Vázquez-Ríos, A.J., Sánchez, L., de la Fuente, M.
- ID
- ZDB-PUB-210512-4
- Date
- 2021
- Source
- Scientific Reports 11: 9873 (Journal)
- Registered Authors
- Keywords
- none
- MeSH Terms
-
- Administration, Cutaneous
- Animals
- Antineoplastic Agents/administration & dosage*
- Antineoplastic Agents/pharmacokinetics
- Apoptosis/drug effects
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cell Survival/drug effects
- Drug Compounding/methods
- Emulsions
- Excipients/chemistry
- Female
- Humans
- Nanoparticles/administration & dosage*
- Nanoparticles/chemistry
- Permeability
- Phosphatidylcholines/chemistry
- Phospholipid Ethers/administration & dosage*
- Phospholipid Ethers/pharmacokinetics
- Skin/metabolism
- Triglycerides/chemistry
- Triple Negative Breast Neoplasms/drug therapy*
- Triple Negative Breast Neoplasms/pathology
- Xenograft Model Antitumor Assays
- Zebrafish
- PubMed
- 33972572 Full text @ Sci. Rep.
Citation
Saraiva, S.M., Gutiérrez-Lovera, C., Martínez-Val, J., Lores, S., Bouzo, B.L., Díez-Villares, S., Alijas, S., Pensado-López, A., Vázquez-Ríos, A.J., Sánchez, L., de la Fuente, M. (2021) Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Scientific Reports. 11:9873.
Abstract
Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelfosine, an alkyl-lysophospholipid, has proved to be a promising therapy for several cancer types, upon delivery in lipid nanoparticles. Therefore, the objective of this work was to explore the potential of edelfosine for the treatment of TNBC. Edelfosine nanoemulsions (ET-NEs) composed by edelfosine, Miglyol 812 and phosphatidylcholine as excipients, due to their good safety profile, presented an average size of about 120 nm and a neutral zeta potential, and were stable in biorelevant media. The ability of ET-NEs to interrupt tumor growth in TNBC was demonstrated both in vitro, using a highly aggressive and invasive TNBC cell line, and in vivo, using zebrafish embryos. Importantly, ET-NEs were able to penetrate through the skin barrier of MDA-MB 231 xenografted zebrafish embryos, into the yolk sac, leading to an effective decrease of highly aggressive and invasive tumoral cells' proliferation. Altogether the results demonstrate the potential of ET-NEs for the development of new therapeutic approaches for TNBC.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping